Showing 1 posts of 1 posts found.

Boehringer’s Gilotrif approved in US for lung cancer with non-resistant EGFRs

January 16, 2018
Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, Cancer, FDA, Giltrif, NSCLC, lung cancer

Boehringer Ingelheim is celebrating the FDA’s decision to expand the indication of its lung cancer drug Gilotrif (afatinib) to include …

Latest content